23 Jun 2021 --- DSM is continuing its journey into the cannabinoid space with an exclusive commercial partnership with Brains Bioceutical, which is active in cannabinoid active pharmaceutical ingredients (APIs). The partnership will create a platform for DSM to help agile early-stage drug development unlock and deliver value-added cannabinoid-based products. These aim to benefit global patient health while having a sustainable, secure supply.
